- ISIN
- US68572M1062
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 4, 2020
Highlights
- Market Cap
- $255.91B
- Enterprise Value
- $255.88B
- EPS (TTM)
- -$0.00
- Total Revenue (TTM)
- $32.72M
- Gross Profit (TTM)
- $32.55M
- EBITDA (TTM)
- -$54.72M
- Year Range
- $2.20 - $5.42
- Target Price
- $12.00
- ROA (TTM)
- -54.25%
- ROE (TTM)
- -132.55%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
OBIO Performance Chart
Orchestra BioMed Holdings Inc. (OBIO) is down 1.7% since the beginning of the year. At $4 per share, OBIO is trading 24.8% below its 52-week high of $5. Investors who bought $1,000 worth of OBIO shares 5 years ago would now be looking at an investment worth $404.
Loading charts...
Returns By Period
Orchestra BioMed Holdings Inc. (OBIO) has returned -1.69% so far this year and 35.55% over the past 12 months.
Orchestra BioMed Holdings Inc.
- 1D
- 2.26%
- 1M
- 0.49%
- YTD
- -1.69%
- 6M
- -7.48%
- 1Y
- 35.55%
- 3Y*
- -21.27%
- 5Y*
- -16.58%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
OBIO Monthly Returns History
Based on dividend-adjusted daily data since Aug 4, 2020, OBIO's average daily return is +0.06%, while the average monthly return is +0.92%. At this rate, an investment would double in approximately 6.3 years.
Historically, 42% of months were positive and 58% were negative. The best month was Mar 2023 with a return of +109.3%, while the worst month was Jun 2023 at -53.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, OBIO closed higher 44% of trading days. The best single day was Mar 6, 2023 with a return of +58.1%, while the worst single day was Apr 1, 2025 at -24.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.90% | 25.50% | -2.97% | -6.12% | -2.01% | 4.35% | -1.69% | ||||||
| 2025 | 31.00% | -10.50% | -8.74% | -30.61% | -4.04% | -5.96% | 14.18% | -10.78% | -9.16% | 57.26% | 36.41% | -21.99% | 3.75% |
| 2024 | -22.45% | -9.04% | -18.17% | -16.32% | 57.14% | 17.60% | -9.45% | -9.21% | -23.28% | 0.19% | 9.32% | -28.95% | -56.19% |
| 2023 | -12.83% | 7.47% | 109.30% | -17.73% | -6.83% | -53.33% | -16.14% | 6.30% | 39.74% | -46.22% | 32.62% | 46.78% | -8.52% |
| 2022 | -2.18% | 0.20% | 0.30% | 0.25% | 0.15% | 0.10% | -0.30% | -0.91% | 0.61% | 0.81% | -0.80% | 0.81% | -0.99% |
| 2021 | -7.65% | 4.99% | -9.90% | -2.23% | -6.13% | -0.68% | -2.84% | -1.21% | 1.02% | -0.30% | 0.10% | 2.13% | -21.31% |
Benchmark Metrics
Orchestra BioMed Holdings Inc. has an annualized alpha of 2.61%, beta of 0.85, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since August 04, 2020.
- This stock participated in 129.71% of S&P 500 Index downside but only 14.57% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2.61%
- Beta
- 0.85
- R²
- 0.03
- Upside Capture
- 14.57%
- Downside Capture
- 129.71%
Return for Risk
Risk / Return Rank
OBIO ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Orchestra BioMed Holdings Inc. (OBIO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| OBIO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.52 | ||
| Sortino ratioReturn per unit of downside risk | -1.53 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.37 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | 1.03 | 2.78 | -1.76 |
| Martin ratioReturn relative to average drawdown | 1.83 | 12.44 | -10.61 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Orchestra BioMed Holdings Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Orchestra BioMed Holdings Inc. was 89.40%, occurring on Sep 23, 2025. The portfolio has not yet recovered.
The current Orchestra BioMed Holdings Inc. drawdown is 81.61%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -89.40%Sep 2025 | 2y 5mo | — | 3y 2moApr 2023 - now |
2023 bear market2023 | -42.60%Feb 2023 | 1y 12mo | 20d | 2y 17dFeb 2021 - Mar 2023 |
2023 bear market2023 | -33.00%Mar 2023 | 10d | 14d | 24dMar 2023 - Mar 2023 |
2020 correction2020 | -14.37%Nov 2020 | 2mo 29d | 1mo 26d | 4mo 25dAug 2020 - Dec 2020 |
2021 correction2021 | -13.31%Jan 2021 | 22d | 12d | 1mo 4dJan 2021 - Feb 2021 |
Drawdown Indicators
| OBIO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.40% | -56.78% | -32.62% |
Max Drawdown (1Y)Largest decline over 1 year | -34.77% | -9.10% | -25.67% |
Max Drawdown (3Y)Largest decline over 3 years | -78.18% | -18.90% | -59.28% |
Max Drawdown (5Y)Largest decline over 5 years | -89.40% | -25.43% | -63.97% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -81.61% | -1.80% | -79.81% |
Average DrawdownAverage peak-to-trough decline | -51.68% | -10.71% | -40.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.50% | 2.03% | +17.47% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Orchestra BioMed Holdings Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Orchestra BioMed Holdings Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for OBIO relative to other companies in the Biotechnology industry. Currently, OBIO has a P/S ratio of 1,958.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for OBIO in comparison with other companies in the Biotechnology industry. Currently, OBIO has a P/B value of 8,144.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with OBIO
Add Orchestra BioMed Holdings Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with OBIO